Physician profile
Jamie Nolan
NPI 1982838652
$3,135.42
in general payments reported to CMS, 2019-2025
40 companies · $607 in 2025
The $607 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $258 · 2021: $583 · 2022: $370 · 2023: $283 · 2024: $157 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.01 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $640.18 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Allergan, INC. | $241.88 | 2019-2020 | |
| Astellas Pharma US INC | $189.57 | 2024-2025 | Veozah |
| Abbvie INC. | $146.33 | 2019-2021 | |
| Abbott Laboratories | $133.25 | 2023 | Proclaim |
| Merck Sharp & Dohme LLC | $127.09 | 2019-2023 | Vaxneuvance, M-M-R II, Proquad |
| Misonix INC | $114.14 | 2019 | |
| Mayne Pharma Commercial LLC | $104.16 | 2021-2025 | |
| Pfizer INC. | $85.59 | 2019-2025 | |
| Hologic Sales and Service, LLC | $74.29 | 2023-2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Duchesnay USA Incorporated | $71.11 | 2019 | |
| Exeltis, USA INC. | $67.34 | 2019-2020 | |
| Acessa Health INC. | $65.32 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $65.08 | 2021 | |
| Millicent US INC | $62.76 | 2025 | Femlyv, Intrarosa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.